Leerink Swann Lowers Ra Pharmaceuticals (NASDAQ:RARX) to Market Perform

Leerink Swann downgraded shares of Ra Pharmaceuticals (NASDAQ:RARX) from an outperform rating to a market perform rating in a report issued on Friday morning. They currently have $48.00 target price on the stock.

A number of other equities analysts also recently commented on the stock. Raymond James downgraded shares of Ra Pharmaceuticals from a strong-buy rating to a market perform rating in a research note on Monday, July 29th. Royal Bank of Canada reissued a sector perform rating and issued a $48.00 price objective on shares of Ra Pharmaceuticals in a research note on Friday. Robert W. Baird downgraded shares of Ra Pharmaceuticals from an outperform rating to a neutral rating and set a $48.00 price objective for the company. in a research note on Thursday. ValuEngine downgraded shares of Ra Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Finally, Jefferies Financial Group lowered shares of Ra Pharmaceuticals from a buy rating to a hold rating and set a $48.00 price target on the stock. in a report on Thursday. One analyst has rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company. The company presently has an average rating of Hold and a consensus price target of $44.25.

Shares of Ra Pharmaceuticals stock traded up $0.40 on Friday, hitting $46.94. 1,670,557 shares of the company traded hands, compared to its average volume of 609,640. The stock’s 50 day moving average price is $26.42 and its 200-day moving average price is $26.30. The company has a current ratio of 15.30, a quick ratio of 15.30 and a debt-to-equity ratio of 0.02. Ra Pharmaceuticals has a 52 week low of $11.27 and a 52 week high of $46.95. The company has a market cap of $2.15 billion, a PE ratio of -22.79 and a beta of 1.34.

Ra Pharmaceuticals (NASDAQ:RARX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.03). As a group, research analysts anticipate that Ra Pharmaceuticals will post -1.97 EPS for the current fiscal year.

In other news, insider Simon Read sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $32.95, for a total transaction of $329,500.00. Following the sale, the insider now directly owns 16,234 shares of the company’s stock, valued at $534,910.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $25.26, for a total transaction of $267,629.70. Following the sale, the insider now directly owns 8,521 shares in the company, valued at $215,240.46. The disclosure for this sale can be found here. Insiders sold 40,595 shares of company stock worth $1,128,930 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. United Services Automobile Association grew its holdings in shares of Ra Pharmaceuticals by 6.3% during the second quarter. United Services Automobile Association now owns 78,944 shares of the company’s stock valued at $2,374,000 after buying an additional 4,687 shares during the last quarter. Nuveen Asset Management LLC purchased a new stake in shares of Ra Pharmaceuticals during the second quarter valued at $6,576,000. UBS Asset Management Americas Inc. grew its holdings in shares of Ra Pharmaceuticals by 1.1% during the second quarter. UBS Asset Management Americas Inc. now owns 318,310 shares of the company’s stock valued at $9,572,000 after buying an additional 3,478 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Ra Pharmaceuticals by 184.8% during the second quarter. Point72 Asset Management L.P. now owns 583,813 shares of the company’s stock valued at $17,555,000 after buying an additional 378,813 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Ra Pharmaceuticals by 28.9% during the second quarter. AQR Capital Management LLC now owns 33,647 shares of the company’s stock valued at $1,012,000 after buying an additional 7,549 shares during the last quarter. 91.59% of the stock is currently owned by hedge funds and other institutional investors.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Story: How to Invest in a Bull Market

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.